Vaxcyte, Inc. PCVX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $794.31M+66.6% | $476.64M+43.4% | $332.34M+96.1% | $169.45M+116% | ||
| $129.37M+39.3% | $92.9M+53.1% | $60.7M+52.5% | $39.81M+57.6% | ||
| $923.68M+62.2% | $569.55M+21.7% | $468.04M+102% | $232.26M+124% | ||
| $923.68M+62.2% | $569.55M+21.7% | $468.04M+102% | $232.26M+124% | ||
| -$923.68M-62.2% | -$569.55M-21.7% | -$468.04M-102% | -$232.26M-124% | ||
| $119.72M+8.8% | $109.99M+74.9% | $62.91M+653% | $8.36M+2,336% | ||
| $157.05M+48.7% | $105.62M+60.6% | $65.78M+650% | $8.77M+144% | ||
| -$766.63M-65.2% | -$463.93M-15.3% | -$402.27M-80.0% | -$223.49M-123% | ||
| -$5.62-47.9% | -$3.80+8.0% | -$4.13-20.4% | -$3.43-78.6% | ||
| -$5.62-47.9% | -$3.80+8.0% | -$4.13-20.4% | -$3.43-77.7% | ||
| 544M+14.6% | 474.6M+23.9% | 383.1M+56.2% | 245.2M+18.6% | ||
| 544M+14.6% | 474.6M+23.9% | 383.1M+56.2% | 245.2M— | ||
| $0— | $0-100% | $75M+226% | $23M— | ||
| $37.33M+953% | -$4.38M— | —— | $8.77M+144% | ||
| -$923.68M-62.2% | -$569.55M-21.7% | -$468.04M-102% | -$232.26M-124% | ||
| -$907.28M-61.3% | -$562.54M-21.0% | -$464.89M-103% | -$229.42M-125% | ||
| -$907.28M-61.3% | -$562.54M-21.0% | -$464.89M-103% | -$229.42M-125% | ||
| -$923.68M-62.2% | -$569.55M-21.7% | -$468.04M-102% | -$232.26M-124% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Vaxcyte, Inc. profitable?
- Vaxcyte, Inc. is not currently profitable: it reported a net loss of $946.5M over the trailing twelve months.
- What is Vaxcyte, Inc.'s earnings per share?
- Vaxcyte, Inc.'s diluted EPS over the trailing twelve months is $-6.88.
- Where does Vaxcyte, Inc.'s income statement data come from?
- Every line is extracted from Vaxcyte, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.